Genome Med July 2023 PMID 37475004

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer.

Yeon Hee Park, Seock-Ah Im, Kyunghee Park, Ji Wen, Kyung-Hun Lee, Yoon-La Choi, Won-Chul Lee, Ahrum Min, Vinicius Bonato, Seri Park, Sripad Ram, Dae-Won Lee, Ji-Yeon Kim, Su Kyeong Lee, Won-Woo Lee

Download social card

Mentions

Peak: 1 in Jun 2021

across 3 sources since Jun 2021

Extended reach

325

potential audience

Total likes

Video views

Mentions per month

Jun 2021 – Oct 2023

Where it's discussed

X / Twitter2 posts
Bluesky1 posts
YouTube1 videos

AI synopsis

What people are saying

Discussions express high interest with references to the study's focus on molecular mechanisms and resistance markers, using words like 'significant' and 'promising.' The tone conveys respect and curiosity, though some comments are more reserved, emphasizing potential rather than immediate impact.

AgreementModerate agreement

Most discussions acknowledge the importance of understanding resistance mechanisms, showing general support for the research outcomes.

InterestHigh interest

Participants demonstrate a high level of curiosity, referencing detailed study designs and potential implications for treatment.

EngagementModerate engagement

Comments include references to specific molecular findings, like mutations and prognosis markers, indicating moderate engagement.

ImpactModerate impact

The discussions suggest an appreciation for the study's potential to influence future research and clinical approaches, though there's a conservative tone about immediate changes.

Abstract in brief

CDK4/6 therapy combined with endocrine therapy is effective for hormone receptor-positive/human epidermal receptor 2-negative metastatic breast cancer, but resistance occurs often and its causes aren't fully understood.
A study analyzed tumor samples from 89 patients before and after treatment with palbociclib and endocrine therapy to uncover the molecular mechanisms behind this resistance.
The research identified new poor prognosis markers and significant genomic changes, including mutations that could help explain why some tumors do not respond well to the treatment and may help in developing strategies to tackle this resistance.

Read the full abstract

All mentions

Understanding Resistance Mechanisms in HR-Positive Breast Cancer Treatments

This study analyzes molecular changes in metastatic breast cancer patients undergoing palbociclib and endocrine therapy, identifying markers and genomic alterations linked to treatment resistance, aiming to improve…

Medicine RTCL TV · Oct 21, 2023 20 views

Fanying Tang

@FanyingTang · X

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer | Genome Medicine | Full Text https://t.co/VSdbKvKwx3

Aug 7, 2023 · 277 followers View post →

cancerpapers

@cancer_papers · X

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer https://t.co/JDsLGatJM0 https://t.co/oUqnmo4Lp2

Jul 21, 2023 · 1 like · 29 followers View post →

Kelly Shanahan

@stage4kelly.bsky.social · Bluesky

This is "Prospective longitudinal multi-omics study of palbociclib resistance in hormone receptor+/HER2- metastatic breast cancer", Yeon Hee Park et al, abstract 1013

Jun 5, 2021 View post →